Project Grant R21AI181698
Award Date
8/7/24
Completion Date
6/30/26
Dollars Obligated
$411K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Honolulu, HI 96813, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $340,712 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Rochester. The grant, titled "Evaluating the Role of Monocytes in the Development of an Effective HIV Vaccine Response", aims to investigate the role of monocyte subpopulations in regulating the antibody response to HIV vaccines. The research project, scheduled for completion by June 30, 2027,...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $769,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant, awarded on July 9, 2025, will support research investigating how the cellular protein SAMHD1 regulates innate immune responses and HIV-1 gene expression in macrophages. The research aims to define the mechanisms by which SAMHD1 suppresses type I interferon induction and NF-kB activation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of California, Davis. The grant, titled "OPTIMAL T-CELL SUPPORT FOR HIV NEUTRALIZING ANTIBODY INDUCTION TO FUSION PEPTIDE-INCLUSIVE REGIMENS (OPTI-FLIP)", will fund the development of an HIV vaccine regimen that elicits cooperative interactions between fusion peptide-directed...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $242,310 to Emory University to study how genetic diversity in the immunoglobulin heavy chain locus impacts the development of neutralizing antibodies against the HIV envelope protein. The project aims to: 1) Identify polymorphisms in rhesus macaques vaccinated with the BG505 SOSIP.664 HIV immunogen that are associated with differential...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $742,463 in funding to the University of Washington to conduct research on HIV envelope glycoprotein vaccines. The goal is to leverage sequence diversity and glycan holes in naturally occurring HIV envelope proteins to design vaccine immunogens that can induce broadly neutralizing antibodies. The research approach involves in silico modeling,...